Loading patent…
AssigneeLytix Biopharma AS
InventorsJohn Sigurd Svendsen, Bengt Erik Haug, Istvan Marko, Oystein Rekdal, Merete Linchausen Skar, Wenche Stensen, Morten Bohmer Strom
Estimating the term…
The invention relates to the use of a molecule comprising a backbone of 2 to 35 non-hydrogen atoms in length, having covalently attached thereto at least two bulky and lipoophilic groups and having at least one more cationic than anionic moiety, in the manufacture of a medicament for destabilising microbial cell membranes and the use as a membrane acting antimicrobial agent of a molecule comprising a backbone of 2 to 35 non-hydrogen atoms in length, having covalently attached thereto a super bulky and lipophilic group comprising at least 9 non-hydrogen atoms and having at least two more cationic than anionic moieties and to methods of treatment involving such molecules, in particular peptides including peptide derivatives, and peptidomimetics.
Use of a molecule comprising a backbone of 4 to 20 non-hydrogen atoms in length, having covalently attached thereto at least two bulky and lipophilic groups and having at least one more cationic than anionic moiety, in the manufacture of a medicament for destabilising microbial cell membranes.
Use as a membrane acting antimicrobial agent of a molecule comprising a backbone of 4 to 20 non-hydrogen atoms in length, having covalently attached thereto at least two bulky and lipophilic groups and having at least one more cationic than anionic moiety.
A use as claimed in any preceding claim wherein each bulky and lipophilic group comprises at least 5 non-hydrogen atoms.
A use as claimed in any preceding claim wherein at least one bulky and lipophilic group incorporates a closed ring of at least 6 non-hydrogen atoms.
Use of a molecule comprising a backbone of 4 to 20 non-hydrogen atoms in length, having covalently attached thereto a super bulky and lipophilic group comprising at least 9 non-hydrogen atoms and having at least two more cationic than anionic moieties, in the manufacture of a medicament for destabilising microbial cell membranes.
Use as a membrane acting antiimicrobial agent of a molecule comprising a backbone of 4 to 20 non-hydrogen atoms in length, having covalently attached thereto a super bulky and lipophilic group comprising at least 9 non-hydrogen atoms and having at least two more cationic than anionic moieties.
A use as claimed in any preceding claim wherein the backbone is 4 to 12 non-hydrogen atoms in length.
A use as claimed in any preceding claim wherein the backbone is linear.
A method of destabilising microbial cell membranes in a patient suffering from a or at risk of being affected by a microbial infection, which comprises administering to said patient a molecule as defined in any preceding claim.
A bioactive peptide of 5 or 6 amino acids in length which has an unmodified N terminus, all of said amino acids being either cationic or bulky and lipophilic in nature, at least two amino acids being bulky and lipophilic and at least two being cationic.
A bioactive peptide of 5 or 6 amino acids in length which incorporates at least 2 bulky and lipophilic moieties and at least 2 cationic moieties, wherein at least one of said bulky and lipophilic moieties is an artificial bulky and lipophilic moiety or at least one of said cationic moieties is an artificial cationic moiety.
Dependencies are inferred from the claim text.